These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29263886)

  • 1. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells.
    Park HY; Tan PS; Kavishna R; Ker A; Lu J; Chan CEZ; Hanson BJ; MacAry PA; Caminschi I; Shortman K; Alonso S; Lahoud MH
    NPJ Vaccines; 2017; 2():31. PubMed ID: 29263886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Antigen to Clec9A Primes Follicular Th Cell Memory Responses Capable of Robust Recall.
    Kato Y; Zaid A; Davey GM; Mueller SN; Nutt SL; Zotos D; Tarlinton DM; Shortman K; Lahoud MH; Heath WR; Caminschi I
    J Immunol; 2015 Aug; 195(3):1006-14. PubMed ID: 26101322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of B cell responses to Clec9A-targeted antigen.
    Park HY; Light A; Lahoud MH; Caminschi I; Tarlinton DM; Shortman K
    J Immunol; 2013 Nov; 191(10):4919-25. PubMed ID: 24123689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
    Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
    Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
    Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
    J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.
    Lahoud MH; Ahmet F; Kitsoulis S; Wan SS; Vremec D; Lee CN; Phipson B; Shi W; Smyth GK; Lew AM; Kato Y; Mueller SN; Davey GM; Heath WR; Shortman K; Caminschi I
    J Immunol; 2011 Jul; 187(2):842-50. PubMed ID: 21677141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.
    Caminschi I; Proietto AI; Ahmet F; Kitsoulis S; Shin Teh J; Lo JC; Rizzitelli A; Wu L; Vremec D; van Dommelen SL; Campbell IK; Maraskovsky E; Braley H; Davey GM; Mottram P; van de Velde N; Jensen K; Lew AM; Wright MD; Heath WR; Shortman K; Lahoud MH
    Blood; 2008 Oct; 112(8):3264-73. PubMed ID: 18669894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice.
    Caminschi I; Vremec D; Ahmet F; Lahoud MH; Villadangos JA; Murphy KM; Heath WR; Shortman K
    Mol Immunol; 2012 Feb; 50(1-2):9-17. PubMed ID: 22209163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.
    King HAD; Gonelli CA; Tullett KM; Lahoud MH; Purcell DFJ; Drummer HE; Poumbourios P; Center RJ
    PLoS One; 2019; 14(8):e0220986. PubMed ID: 31430333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosting antibody responses by targeting antigens to dendritic cells.
    Caminschi I; Shortman K
    Trends Immunol; 2012 Feb; 33(2):71-7. PubMed ID: 22153931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection.
    Padilla-Quirarte HO; Badillo-Godinez O; Gutierrez-Xicotencatl L; Acevedo-Betancur Y; Luna-Andon JD; Montiel-Hernandez JL; Lopez-Guerrero DV; Esquivel-Guadarrama F
    Vaccine; 2019 May; 37(19):2624-2633. PubMed ID: 30955979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.
    Zhu W; Pewin W; Wang C; Luo Y; Gonzalez GX; Mohan T; Prausnitz MR; Wang BZ
    J Control Release; 2017 Sep; 261():1-9. PubMed ID: 28642154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of protective efficacy induced by different heterologous prime-boost strategies encoding triosephosphate isomerase against Schistosoma japonicum in mice.
    Dai Y; Zhao S; Tang J; Xing Y; Qu G; Dai J; Jin X; Wang X
    Parasit Vectors; 2017 Feb; 10(1):111. PubMed ID: 28241779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells.
    Chan JD; von Scheidt B; Zeng B; Oliver AJ; Davey AS; Ali AI; Thomas R; Trapani JA; Darcy PK; Kershaw MH; Dolcetti R; Slaney CY
    Clin Transl Immunology; 2020; 9(7):e1157. PubMed ID: 32704371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine.
    Apostólico JS; Lunardelli VA; Yamamoto MM; Souza HF; Cunha-Neto E; Boscardin SB; Rosa DS
    Front Immunol; 2017; 8():101. PubMed ID: 28223987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Influenza Virus Hemagglutinin to Xcr1
    Gudjonsson A; Lysén A; Balan S; Sundvold-Gjerstad V; Arnold-Schrauf C; Richter L; Bækkevold ES; Dalod M; Bogen B; Fossum E
    J Immunol; 2017 Apr; 198(7):2785-2795. PubMed ID: 28228559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-12p40/IL-10 Producing preCD8α/Clec9A+ Dendritic Cells Are Induced in Neonates upon Listeria monocytogenes Infection.
    Torres D; Köhler A; Delbauve S; Caminschi I; Lahoud MH; Shortman K; Flamand V
    PLoS Pathog; 2016 Apr; 12(4):e1005561. PubMed ID: 27074026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKT Cell-Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion.
    Lam PY; Kobayashi T; Soon M; Zeng B; Dolcetti R; Leggatt G; Thomas R; Mattarollo SR
    Cancer Immunol Res; 2019 Jun; 7(6):952-962. PubMed ID: 31053598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine.
    Luijkx T; van Dijken H; van Els C; van den Dobbelsteen G
    Vaccine; 2006 Mar; 24(10):1569-77. PubMed ID: 16298029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.